Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies.
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A random effect meta-analysis yielding Hedges' g ±95% confidence intervals (CIs) as the effect size measure (ES) was conducted. Primary outcome was a pooled composite of pain threshold, pain tolerance, and sensory threshold; secondary outcomes included these parameters individually, plus physiological pain response, and pain intensity/unpleasantness. Across 17 studies, schizophreniaspectrum disorder patients (n=387, age=30.7±6.9 years, female=31.9%, illness duration=7.0±5.7 years) were compared with controls (n=483, age=29.5±7.4 years, female=31.0%). Patients had elevated pain threshold/pain tolerance/sensory threshold versus controls (ES=0.493, 95% CI=0.145-0.839, p=0.005; studies=17). Results were similar in antipsychotic-free individuals (ES=0.599, 95%
CI=0.291-0.907, p<0.0001; studies=8), with trend-level significance in antipsychotic-treated individuals (ES=0.428, 95%CI=-0.059-0.915, p=0.085; studies=11). Likewise, schizophrenia patients had increased pain tolerance (ES=0.566, 95% CI=0.235-0.897, p=0.0001; studies=6), sensory threshold (ES=1.16, 95% CI=0.505-1.727, p<0.0001; studies=5) and pain threshold (ES=0.696, 95% CI 0.407-0.986, p<0.001; studies=9), and reduced physiological response to painful stimuli (ES=0.456, 95%CI=0.131-0.783, p=0.006) and pain intensity/unpleasantness ratings (ES=0.547, 95% CI=0.146-0.949, p=0.008). Findings were similarly significant in antipsychotic-free schizophrenia patients (analyzable parameters=4) and antipsychotic-treated individuals (analyzable parameters=2). Finally, greater psychiatric symptoms and younger patient age moderated increased pain tolerance/threshold. Decreased pain sensitivity seems to be an endophenotype of schizophreniaspectrum disorders. How this alteration links to other dimensions of schizophrenia and physical comorbidity-related help-seeking behaviour/morbidity/mortality requires further study. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65
Introduction
Research has consistently demonstrated that people with schizophrenia experience an increased number of painful physical health comorbidities, including fractures [48] , diabetes [50] and cardiovascular diseases, such as myocardial infarction [19; 37] . For over 60 years, numerous case reports and case series indicated that people with schizophrenia have reduced pain sensitivity [16] leaving clinicians perplexed when this population appears not to report pain in the face of ordinarily painful comorbidities. For instance, Lieberman [38] established that over 85% of patients with psychosis experiencing myocardial infarction did not report experiencing pain. This finding has been replicated numerous times since. For example, Hussar [27; 28] found that 60% of people with schizophrenia that died from a coronary heart disease reported no pain. This phenomenon persists to the present day and despite the high rates of cardiometabolic abnormalities in people with schizophrenia [52] , it is noteworthy that there is a negligible increase of patients with schizophrenia presenting to hospitals with heart disease compared to the general population [35] , which may contribute to the established increased premature mortality in people with schizophrenia [12; 41] .
Consistent with the possibility of reduced pain sensitivity in schizophrenia, Stubbs et al [49] found that the prevalence of pain in those with schizophrenia was comparable to that of controls in a meta-analysis of over 5 million people (relative risk (RR)=0.99, 95% CI=0.83-1.19), despite the fact that schizophrenia is linked to a greater number of conditions ordinarily associated with pain [11; 12; 48] . Whilst the review of Stubbs et al [49] was helpful, the reliance on pain data from self-report and lack of pain severity measures in most studies might have introduced bias and noise. For example, cognitive deficits may impede the ability of people with schizophrenia to recognise and communicate the presence of pain [7] . In addition, the investigation of the prevalence of pain in schizophrenia patients is further complicated by the fact that antipsychotic medications have analgesic properties [45] . Nevertheless, understanding if people with schizophrenia have reduced pain sensitivity has important implications and poses a central clinical challenge, since a patient's inability to recognise pain may lead to increased risk for morbidity and ultimately mortality [29] .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Experimental pain testing methods circumvent some of the concerns associated with data obtained from a purely clinical setting. Firstly, they allow for precise controllability of the noxious stimulus ensuring equivalent stimulation across groups. Secondly, they facilitate the recording of 'objective' non-verbal measures of pain, typically autonomic stress indices such as heart rate and pupillary dilation and thus offer a superior method for investigating algesia and hypoalgesia in people with schizophrenia. When considering experimental studies, it is important to establish the methods of pain induction (e.g., thermal, mechanical, chemical) and measurement including (1) pain threshold,
(2) pain tolerance, (3) sensory threshold, (4) physiological responses to painful stimuli, and (5) ratings of pain intensity/unpleasantness [23] . It remains unclear to what extent people with schizophrenia have reduced pain sensitivity in each of these measures of pain.
Only one previous review [43] , with a last search date of almost a decade ago, investigated differences in experimental pain responses in people with schizophrenia versus controls. The authors aggregated all different types of pain measures together in a composite analysis and found that people with schizophrenia appeared to exhibit hypoalgesia. Whilst this review advanced the field, the authors included only 11 studies and 497 participants in a composite analysis in which they pooled any pain measures per study. Moreover, the authors were only able to pool data from 3 and 6 studies to investigate sensory threshold and pain threshold, respectively. Thus, only 2 of the 5 dimensions of pain sensitivity in people with schizophrenia were explored in that prior review.
Other important facets of pain sensitivity, such as pain tolerance, physiological responses to painful stimuli, and ratings of pain intensity/unpleasantness were not explored, but may have important implications. In addition, pooling data on physiological responses to pain may offer a unique insight that circumvents concerns regarding cognitive and communication deficits when recognising and reporting pain in schizophrenia [7] .
Given the importance of pain sensitivity in schizophrenia and lack of a comprehensive analysis of the available data of experimental pain studies, we aimed to investigate if people with schizophrenia- spectrum disorders have reduced pain sensitivity under experimental pain conditions, assessing the different dimensions of pain. Based on the available data, we hypothesized that people with schizophrenia would exhibit decreased pain sensitivity in the form of reduced physiological response and ratings of pain and increased pain tolerance and threshold. We further hypothesized that these findings would be accentuated in antipsychotic-free patients. 
Method
This systematic review was conducted in accordance with the MOOSE guidelines [47] and in line with the PRISMA statement [40] , following a predetermined, but unpublished protocol.
Inclusion criteria
Included in this meta-analysis were studies that: (1) Included adult participants with schizophreniaspectrum disorders (schizophrenia, schizoaffective disorder, schizophreniform disorder, as well as samples with >50% non-affective psychotic), diagnosed according to established criteria (e.g., DSM-IV, [2] or ICD-10, [42] ); (2) Investigated any type of experimentally induced pain reporting data on (a) pain threshold, (b) pain tolerance, (c) sensory threshold, (d) physiological responses to noxious stimuli, or (e) ratings of pain intensity/ unpleasantness; (3) reports comparative data in a healthy control group; and (4) were published in an international peer-reviewed journal or conference abstract.
Information sources and searches
Three independent reviewers (BS, TT, SA) searched Academic Search Premier, MEDLINE, Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed without language restrictions from database inception until April 15th, 2015, using the key words 'schizophrenia' or 'schiz*' or 'psychosis' or 'psychoses' or 'psychotic' and 'pain*' or 'nociception' or 'cold' or 'heat' or 'electrical' or 'thermal' or 'reflex' 'hypoalgesia'. In addition, reference lists of all eligible articles and reviews of pain in schizophrenia were screened to identify additional studies.
We contacted corresponding/first authors up to 3 times over a month to clarify study eligibility and/or acquire additional data. After removal of duplicates, two independent reviewers screened the titles and abstracts of all potentially eligible articles. Two authors applied the eligibility criteria, and a list of full text articles was developed through consensus. Two authors (BS, TT) considered the full texts of included articles and a final list of included articles was reached through consensus.
Study selection

Outcomes:
Primary outcome was a composite of selected measures of pain sensitivity that was derived by pooling the means and SDs of the following 3 individual parameters: (1) pain threshold, (2) pain tolerance, (3) sensory threshold. These 3 parameters were selected, as threshold and tolerance are typically correlated (e.g. [51] ). Secondary outcomes were these three parameters by themselves plus two additional individual outcomes, namely (4) physiological responses to painful stimuli, and (5) ratings of pain intensity/unpleasantness.
Data Extraction
Two authors (TT, BS) extracted data using a data extraction form, including: study design, geographical location, details of schizophrenia participants (mean age, % males, diagnosis and utilized criteria, first episode, duration of illness body mass index, psychopathology scores, psychopharmacologic treatment, including % on antipsychotics (including type), antidepressants and mood stabilisers), and type and method of experimental pain measure assessment. We also abstracted details regarding the control group, including mean age, sex and body mass index.
Finally, we extracted data on the mean and standard deviation (SD) for each experimental pain measurement.
When studies reported data from the same sample at different time points, we used the most recent data and/or the largest data set. From duplicate studies reporting experimental pain data in participants before and after antipsychotic medication treatment, we included the antipsychoticfree data for the overall pooled analyses, but also used the data in antipsychotic-treated patients in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 subgroup analyses. Studies that employed sensory decision theory to determine pain threshold reported two measures: response criterion and d' (sensory discrimination). Response criterion was abstracted as the data of interest, as this measure is the most closely related to pain threshold used in the other included studies, which assessed pain threshold through verbal declaration [23] .
Meta-analysis
Due to the anticipated heterogeneity, we adopted the random effects meta-analysis and calculated
Hedges's g 95% confidence intervals (CIs) as the effect size measure (ES) comparing pain sensitivity between participants with schizophrenia-spectrum disorders (henceforward called "schizophrenia") and controls using Comprehensive Meta-Analysis (CMA, Version 3). In line with a previous metaanalysis [43] , we examined the funnel plot of the composite outcome searching for extreme outliers and removed from the database and all analyses one extreme publication bias outlier [39] . Across the resultant sample of 17 studies, we first conducted a composite analysis pooling aggregated pain measure data on pain threshold, pain tolerance and sensory threshold together from all studies to establish an overall difference in pain sensitivity. We further pooled data separately for: (1) pain threshold, (2) pain tolerance, (3) sensory threshold, (4) physiological responses to painful stimuli, and (5) ratings of pain intensity/unpleasantness. We conducted subgroup analyses for the composite and each individual pain measure in patients who were antipsychotic-free or antipsychotic-treated at the time of experimental pain induction and assessment. Additional exploratory analyses compared the composite score in the same population off and on antipsychotics in those studies were patients were reassessed after antipsychotics were started. Heterogeneity was assessed with the I 2 statistic for each analysis [26] . Furthermore, we conducted meta-regression analysis with CMA when data were available in at least 3 studies, assessing the moderating effects of mean age, % females in both cohorts separately, and duration of illness and summary scores of psychiatric symptoms (measured with a standardised scale, e.g., PANSS [32] ) in the schizophrenia cohort. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Publication bias was assessed with a visual inspection of funnel plots and with the Begg-Mazumdar Kendall's tau [4] and Egger bias test [17] .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Results
Study selection, Study and participant characteristics
The initial search yielded 2532 hits. After removal of duplicates, 1989 abstracts and titles were screened. A further 20 abstracts were screened following a review of references from previous systematic reviews [7; 43] . At the full text review stage, 28 articles were considered and 11 were subsequently excluded (see Figure 1 for search results 46]. One publication [15] contained two unique studies with different samples and is henceforth considered as two unique studies. Full details of the included studies are summarised in Table 1 . whilst two induced pain mechanically [21; 46] . Details of each study, including medication data (where available), pain modalities and assessed parameters are summarised in table 1.   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  Table 2 Meta-analysis investigating pain sensitivity in people with psychosis
In the composite analysis of 17 unique samples, people with schizophrenia had reduced pain sensitivity versus controls (ES=0.493, 95% CI=0.145-0.839, p=0.005; I 2 =81%, n=847; Table 2 , figure 2 ).
There was no evidence of publication bias (Begg=0.08, p=0.60, Egger test=4.56, p=0.18).
Figure 2 here
In a subgroup analysis, results were confirmed in antipsychotic-free patients (ES=0.599, 95%
CI=0.291-0.907, p<0.0001, I 2 =41%, studies=8, n=371 In exploratory analyses of composite pain measures before and 5 weeks after antipsychotic initiation in the same patients from two studies (n=35), there was a significant reduction in pain sensitivity after antipsychotics were started (ES=-0.279, 95% CI -0.483 to -0.075, p=0.007, I 2 =0%).
Figure 3 a and b here
Meta-regression of predictors of pain sensitivity
In meta-regression analyses of pain sensitivity across all studies, mean age, percentage of females, illness duration and psychopathology scores did not moderate significantly pain sensitivity (p>0.05, data not shown). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Pain threshold Across 9 studies (n=439), people with schizophrenia had significantly higher pain threshold than controls (ES=0.696, 95% CI 0.407-0.986, p<0.001, I 2 =51%, Begg=0.35, p=0.26, Egger=3.7, p=0.25, table 2). In sub-group analyses, pain threshold was higher than in controls in both antipsychotic-free (ES=0.753, 95% CI 0.305-1.202, p<0.001, I 2 =61%, studies=5, n=252) and antipsychotic-treated participants (ES=0.706, 95% CI 0.354-1.05, P<0.001, I 2 =49%, studies=5, n=195, table 2).
Meta-analysis investigating differences in different pain measures/modalities
Meta-regression of pain threshold
Only greater total psychiatric symptoms severity was a significant moderator of pain threshold (β=0.0156, 95%CI=0.0025-0.0286, z=2.34, p=0.019, R 2 =1.0, studies=4, n=155), explaining the entire between-study variance.
Pain tolerance
Across 7 studies (n=366) pain tolerance did not appear reduced in people with schizophrenia (ES=0.393, 95%CI=-0.048-0.836, p=0.08, I 2 =74%, table 2). However, the funnel plot identified one striking outlier [22] for pain tolerance . After removal of this study, schizophrenia patients had significantly greater pain tolerance than controls (ES=0.566, 95% CI=0.235-0.897, p=0.0001, I 2 =49%, studies=6, Egger=2.26, p=-0.58, Begg=0.13, p=0.70, studies=6, n=330). Subgroup analyses with the outlier removed established similar results in antipsychotic-free (ES=0.342, 95%CI=0.03-0.645, p=0.02, I 2 =41%, studies=4, n=190) and antipsychotic-treated participants (ES=0.745, 95%CI=0.461-1.02, p<0.0001, I 2 =0%, studies=4, n=211) (table 2) .
Meta-regression of pain tolerance
Only a higher mean age of schizophrenia participants significantly moderated pain tolerance (β=-0.058, 95% CI -0.1to-0.0161, z=-2.71, p=0.006, R 2 =1.0, studies=6, n=330). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Across 5 studies (n=294), people with schizophrenia had a higher sensory threshold than controls (ES=1. 16 
Sensory threshold
Meta regression of sensory threshold
No significant moderators were identified.
Physiological responses to pain
Across 4 studies (n=190), the physiological response to pain was significantly reduced in people with schizophrenia compared to controls (ES=0.465, 95% CI=0.131-0.783, p=0.006, I 2 =1%, Begg=0, p=1, Egger=5.1, p=0.73, table 2). Similar results were found in antipsychotic-free individuals (ES=0.505, 95%CI=0.072-0.941, p=0.02, I 2 =28%, studies=3, n=145), whereas no data were available in antipsychotic-treated individuals (table 2) .
Pain rating of intensity/ unpleasantness
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Discussion
Results of the largest and most comprehensive meta-analysis of experimental pain studies in schizophrenia-spectrum disorder patients indicate that 1) across all studies, using a composite outcome, patients had elevated pain threshold/pain tolerance/sensory threshold versus controls; 2) results were similar in antipsychotic-free individuals, but showed only trend level significance in antipsychotic-treated individuals; 3) in 2 longitudinal studies, antipsychotic initiation significantly decreased pain sensitivity; 4) pooling results across individual outcomes, patients had increased pain tolerance, sensory threshold and pain threshold, yet reduced physiological response to painful stimuli and ratings of pain intensity/unpleasantness; 5) after removal of one marked outlier, findings regarding individual outcomes were similarly significant in antipsychotic-free and antipsychotictreated individuals; and 6) in meta-regression analyses, greater psychiatric symptoms and younger patient age moderated increased pain tolerance/threshold.
Our results are consistent with a more preliminary prior meta-analysis [43] . In this paper, the authors had reported hypoalgesia to experimentally induced pain that was independent of antipsychotic treatment using a composite analysis in which any pain measure, albeit very divergent parameters were pooled together. However, that prior quantitative review included only 11 studies and 497 participants compared to our meta-analysis in which we were able to analyse data from 18 unique samples including 870 participants. Furthermore, the prior meta-analysis was only able to pool data individually for sensory threshold and pain threshold, i.e., for only 2 of the 5 specific pain sensitivity dimensions that we were able to analyse separately, which enabled us to confirm and extend the results of decreased pain sensitivity across different pain measures and both in samples on and off antipsychotics.
The exact reasons for the observed deficits in pain sensitivity in people with schizophrenia are complex, likely multifactorial [7; 29] and may, given the heterogeneous nature of schizophrenia, vary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 from patient to patient and over time. Importantly, however, the finding of a blunted physiological response to noxious stimuli confirms for the first time that individuals with schizophrenia genuinely appear to exhibit hypoalgesia rather than simply failing to report pain. Thus, hypoalgesia appears to be an endophenotype of schizophrenia, which could be explained by several neurobiological processes. First, impaired prefrontal and medial temporal functioning in schizophrenia [33] may result in a reduced pain experience. Specifically, prefrontal cortex hypofunctioning may result in alterations in the motivational affective processing of pain [18] which may translate into difficulties in recognising and expressing pain [7; 53] . Second, impairments within the mediodorsal thalamus and hippocamapus (both central parts of the medial pain system) may play a role in modifying affective and cognitive evaluative processes of pain among people with schizophrenia [20] , translating into decreased pain experience. Third, alterations in the cortical dopamine system and higher vulnerability of COMT Met allele may account for reduced pain sensitivity in people with schizophrenia [29] . Fourth, there may also be decreased primary sensory-discriminative pain processing functioning. For example, one study included in our meta-analysis [13] utilised functional magnetic resonance imaging to explore blood oxygen level dependent changes (BOLD) in response to experimentally induced pain in 12 antipsychotic-free people with schizophrenia. The authors found a greater BOLD response in patients in the primary sensory-discriminative pain processing region (S1) compared to controls, and noticed reduced activity in the posterior cingulate cortex, insula and brain stem, suggesting abnormal central processing during painful stimuli. Taken together, these findings suggest decreased pain sensitivity as a potential endophenotype of schizophrenia, which may be relevant to enhance diagnostic precision in general, or predictive validity during the ultra-high risk syndrome for psychosis [9] . Furthermore, studies should investigate if symptomatic response to antipsychotic treatment is related to a normalization of pain sensitivity and/or if baseline values could be predictive of future symptomatic response.
Moreover, due to increased sensory and pain thresholds as well as greater pain tolerance, individuals with schizophrenia may not register potentially harmful stimuli that are related to often 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 co-occurring physical comorbidities until they becomes more advanced, which could possibly contribute to the low help-seeking among people with schizophrenia [11; 12] , since pain is the primary reason that people seek medical help, [25] . Given that people with schizophrenia already experience multiple barriers in accessing medical care [11; 12] these results are concerning.
Antipsychotics are known to be analgesic [45] , which was reflected by our exploratory finding of two longitudinal studies [13; 14; 30] , in which antipsychotic initiation further reduced pain sensitivity.
Nevertheless, hypoalesia was clearly apparent in antipsychotic free individuals, indicating that reduced pain sensitivity appears to be a trait marker that is independent of antipsychotic effects.
Finally, for the first time, we investigated moderators that may explain the reduced pain sensitivity in people with schizophrenia. In meta-regression analyses, greater psychiatric symptoms and younger patient age moderated increased pain tolerance/threshold. Curiously, the inverse age effect is in contrast to increases in pain threshold in older adults in the general population [36] .
Whilst this is the most comprehensive meta-analysis of experimental pain research in participants with schizophrenia to date, a number of limitations need to be considered. First, although we increased the number of studies and participants compared to the previous meta-analysis by 39% and 43%, this meta-analysis still only contains a modest number of studies and participants, especially when considering individual pain parameters. Second, there were insufficient data to investigate pain sensitivity among people with first episode psychosis. Third, there were insufficient details within the included studies to determine if the antipsychotic-free participants were actually antipsychotic-naïve or (more likely) had stopped prior treatment for some (unknown) duration.
Moreover, other psychotropic medications may also have influences pain sensitivity, but data were too sparse to examine this further. Fourth, too few studies examined pain sensitivity in patients before and after antipsychotic treatment, and none examined the relationship between changes in pain sensitivity and psychopathology over time. Finally, some results were heterogeneous. However, we were able to explain this heterogeneity in a number of our meta-regression analyses. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Future experimental research is required to better understand the interaction between different dimensions of schizophrenia and decreased pain sensitivity, such as various aspects of psychopathology, including negative symptoms and cognition, and medication effects (both before and after treatment and in those truly antipsychotic-naïve). Meta-regression analyses suggested that greater global psychiatric symptom severity contribute to reduced pain sensitivity, but it was not possible to investigate the influence of negative symptoms or cognitive deficits within our analyses due to paucity of data. Future work is required to understand these potential interactions.
Research investigating physiological responses to painful stimuli should be increased, given that decreased pain sensitivity may be an endophenotype of schizophrenia and related disorders and that decreased identification and reporting of pain may be directly related to the low help-seeking and insufficient treatment of medical comorbidities in patients with schizophrenia [11; 12] . Finally, research is needed that investigates methods to assist clinicians to identify people with schizophrenia with painful comorbidities and ultimately seeks to demonstrate how this increased detection of pain may improve patient care, morbidity, quality of life and mortality. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Takeda.
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Excluded with reasons N=11
Included in meta-analysis N=17 unique studies (n=387 schizophrenia, n=483 controls) 
5-7
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
6-7
METHODS
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
8
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
8-9
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
9-10
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
10-11
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2 ) for each meta-analysis.
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